G
Graymatters
EEG-based self-neuromodulation therapy for mental health disorders
About Graymatters
Developer of digital therapeutics designed to cure mental illness. The company's digital therapeutics follow the self-regulation of brain processes to solve the issues related to mental health and neurologic disorder, enabling patients suffering from neurological disorders to treat their diseases in a hassle-free manner.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Haifa, Israel
- Employees
- 31
- Open positions
- None listed
- Dealroom signal
- 66.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices, Health Platform
- Sector
- Biotech & Life Sciences, Psychology, Biotechnology, Mental Health, Spinout, EIC, Digital Therapeutics, Biotech and Pharma
- Technology
- Deep Tech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SUPPORT PROGRAM✓Other financing | Nov 2022 | $0 | — | Undisclosed | — |
| SUPPORT PROGRAM✓Other financing | Jan 2022 | $0 | — | 28DIGITAL Accelerator | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Graymatters is 9.2K monthly website visits, up 196.8% over the last three months. Graymatters's team grew 6.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Restorative NeurotechnologiesProducing wearable medical device in order to enhance the strength of the rehabilitation for cognitive disease or enhance sport performance |
Palermo, Italy | Operational | 13 | $4.4M | $13M |
 moveUPAI-powered digital therapy for remote patient monitoring |
City of Brussels, Belgium | Operational | |||
 Mindable HealthDigital therapeutics for anxiety |
Berlin, Germany | Operational | |||
 CroivalveTreating Heart Valve Disease |
Dublin, Ireland | Operational | |||
 GlucosetIntravascular continuous glucose monitoring system for ICUs |
Trondheim, Norway | Operational | |||
 Aenitis TechnologiesDeveloping a cell treatment device |
Paris, France | Operational | |||
 NC BiomatrixDeveloping a patented injectable technology to improve the treatment of intervertebral disc degeneration |
Eindhoven, Netherlands | Operational | |||
 EverZomA key asset to the future health of an ageing population |
Paris, France | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Joyance Partners
European Innovation Council
Series A7 investors entered at this stage
EIC Fund
Otsuka Pharmaceutical
Marius Nacht
J-Impact
GMH Ventures
Joy Ventures
J-Ventures
Other known investors6 additional known investors
28DIGITAL Accelerator
Tel Aviv Sourasky Medical Center
Tel Aviv University
Endless Frontier Labs
Falling Walls Foundation- J Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Graymatters on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Graymatters’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.